ClinicalTrials.gg
Active, not recruitingNCT06401044Updated Aug 10, 2026

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

A Phase 1/2 interventional study of AMG 732 and Placebo in Thyroid Eye Disease, sponsored by Amgen. Active, not recruiting at 44 sites in 12 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Graves Ophthalmopathy by Amgen — 1 open to participants now, 3 under way, 1 of them phase 3. Graves Ophthalmopathy · Amgen.

Enrollment
2nd of 12
94 · median 57
Started
2024
with 1 other
Phase 1/2
Only one
of the 14
Registered
9th of 14
by date

Among the 14 studies in Graves Ophthalmopathy by Amgen, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1/2, and was the 9th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

1 of the 14 studies in Graves Ophthalmopathy by Amgen is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Graves Ophthalmopathy by Amgen, or all of them as a file.
02

Study summary

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Read the detailed description

Recruitment has ended for the Phase 1 portion of the study and will reopen when Phase 2 begins recruitment.

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

Keywords

  • AMG 732
  • Thyroid Eye Disease
  • TED
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria for Part A/Phase 1 only:

  • Participant has provided before initiation of any study-specific activities/procedures.
  • Male or female aged 18 to 55 years (Part A).
  • Female participants must be of non-.
  • (BMI) between 18 and 30 kg/m\^2, inclusive, at screening.
  • The participant has adequate venous access and can receive intravenous (IV) therapy.
  • The participant is considered by the investigator or designee to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead (ECG) results, and physical examination findings at screening.
  • Healthy Japanese participants in cohort 4 only. Japanese participants must meet all the following as confirmed by interview: Descendants of 4 ethnic Japanese grandparents who were born in Japan; Both parents are ethnic Japanese who were born in Japan; Hold a Japanese passport or identity papers; Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan.

Inclusion criteria for Part B/Phase 2 only:

  • Male or female aged 18 to 65 years.
  • Moderate-to-severe active TED.
  • The participant had onset of active TED within 15 months prior to baseline.
  • Clinical diagnosis of Graves' disease associated with active TED with a Clinical Activity Score (CAS)≥3 for the most severely affected eye at screening and baseline.
  • Proptosis ≥18mm in the study eye at baseline.
  • Participants with baseline subjective binocular diplopia score >0.
  • Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.

Exclusion criteria for Part A and Part B:

  • Malignant condition in the past 12 months or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
  • Active liver or kidney disfunction at screening.
  • Positive test for /C or (HIV) serology at screening.
  • (HbA1c) > 6.5% and/or fasting glucose levels> 126 mg/dL (> 7 mmol/L) at screening.
  • Use of any (IV, oral, steroid eye drops) within 3 weeks prior to the first dose. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat injection related reactions or short course of steroid for asthma control.
  • Known to teprotumumab or any other monoclonal antibody products.
  • History of substance abuse within 12 months before screening.
  • Donated blood, or had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to day 1 dosing or received a plasma donation within 7 days prior to day 1 dosing.

Exclusion criteria for PartA/Phase 1 only

  • Blood pressure or ECG abnormalities at screening.

Exclusion criteria for Part B/Phase 2 only:

  • Use of any steroid or other non-steroid agent, monoclonal antibody, within 3 months prior to the first injection of study drug.
  • Use of teprotumumab or any other IGF-1R inhibitor.
  • Prior orbital irradiation or decompression in the study eye.
  • History or existing inflammatory bowel disease (ulcerative colitis or Crohn's disease).

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Part A: AMG 732

    Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).

    Drug: AMG 732

  • Placebo comparator
    Part A: Placebo

    Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).

    Other: Placebo

  • Experimental
    Part B: AMG 732 Low Dose

    Participants will receive AMG 732 low dose SC.

    Drug: AMG 732

  • Experimental
    Part B: AMG 732 Medium Dose

    Participants will receive AMG 732 medium dose SC.

    Drug: AMG 732

  • Experimental
    Part B: AMG 732 High Dose

    Participants will receive AMG 732 high dose SC.

    Drug: AMG 732

  • Placebo comparator
    Part B: Placebo

    Participants will receive placebo SC.

    Other: Placebo

Interventions

  • DrugAMG 732

    SC injection

  • OtherPlacebo

    SC injection

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment-emergent Adverse Events

    Time frame: Day 1 through Week 36 (End of Study)

  2. Part B: Change from Baseline in Proptosis Measurement by an Exophthalmometer in the Study Eye

    Time frame: Baseline to End of Treatment (EoT) (approximately 6 Months)

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of AMG 732

    Time frame: Up to Week 36

  2. Part A: Time to Cmax (Tmax) of AMG 732

    Time frame: Up to Week 36

  3. Part A: Area Under the Plasma Concentration-time Curve (AUC) of AMG 732

    Time frame: Up to Week 36

  4. Part A: Half-life (t1/2) of AMG 732

    Time frame: Up to Week 36

  5. Part A: Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 36

  6. Part B: Number of Participants With Treatment-emergent Adverse Events

    Time frame: Up to Week 48

  7. Part B: Cmax of AMG 732

    Time frame: Up to Week 48

  8. Part B: Tmax of AMG 732

    Time frame: Up to Week 48

  9. Part B: AUC of AMG 732 Over the Dosing Interval

    Time frame: Up to Week 48

  10. Part B: Accumulation of AMG 732 Following Multiple Dosing

    Time frame: Up to Week 48

  11. Part B: Half-life (t1/2) of AMG 732

    Time frame: Up to Week 48

  12. Part B: Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 48

  13. Part B: Proptosis Response Status in the Study Eye

    Time frame: EoT (approximately 6 Months)

  14. Part B: Mean Change from Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Visual Functioning (VF) Subscale Score

    Time frame: Baseline to EoT (approximately 6 Months)

  15. Part B: Mean Change from Baseline in the GO-QoL Appearance (A) Subscale Score

    Time frame: Baseline to EoT (approximately 6 Months)

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 6, 2024
StartActual
May 30, 2024
Primary completionEst.
Jan 6, 2027
CompletionEst.
Dec 24, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06401044
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 6, 2024
Start date
May 30, 2024
Primary completion
Jan 6, 2027 (estimated)
Completion
Dec 24, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion